Premenstrual syndrome and premenstrual dysphoric disorder

American Family Physician

Volumn 84, Issue 8, 2011, Pages 918-924

  Biggs, Wendy S ^a   Demuth, Robin H ^b  

^a AMERICAN ACADEMY OF FAMILY PHYSICIANS   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ALPRAZOLAM; BUSPIRONE; CALCIUM CARBONATE; CITALOPRAM; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESCITALOPRAM; ETHINYLESTRADIOL PLUS NORETHISTERONE; FLUOXETINE; GOSERELIN; HERBACEOUS AGENT; HISTRELIN; LEUPRORELIN; NAFARELIN ACETATE; PAROXETINE; PLACEBO; PYRIDOXINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SPIRONOLACTONE; VENLAFAXINE; VITAMIN D;

ALTERNATIVE MEDICINE; ANXIETY DISORDER; ARTICLE; CALCIUM INTAKE; COGNITIVE THERAPY; CONGENITAL HEART MALFORMATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; GINKGO BILOBA; HUMAN; HYPERICUM PERFORATUM; INSOMNIA; LIBIDO DISORDER; LIFESTYLE MODIFICATION; MULTIPLE CYCLE TREATMENT; NAUSEA; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SOYBEAN; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION; VITEX AGNUS CASTUS;

EID: 80054821653     PISSN: 0002838X     EISSN: 15320650     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 15: Premenstrual syndrome. Obstet Gynecol. 2000;95(4).
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association; 2000:771-774.
3. Dennerstein L, Lehert P, Bäckström TC, Heinemann K. Premenstrual symptoms-severity, duration and typology: an international cross-sectional study. Menopause Int. 2009;15(3):120-126.
4. Potter J, Bouyer J, Trussell J, Moreau C. Premenstrual syndrome prevalence and fluctuation over time: results from a French population-based survey. J Womens Health (Larchmt). 2009;18(1):31-39.
5. Yonkers KA, O'Brien PM, Eriksson E. Premenstrual syndrome. Lancet. 2008;371(9619):1200-1210.
6. Rapkin AJ, Winer SA. Premenstrual syndrome and premenstrual dysphoric disorder: quality of life and burden of illness. Expert Rev Pharmacoecon Outcomes Res. 2009;9(2):157-170.
7. Adewuya AO, Loto OM, Adewumi TA. Pattern and correlates of premenstrual symptomatology amongst Nigerian University students. J Psychosom Obstet Gynaecol. 2009;30(2):127-132.
8. Nisar N, Zehra N, Haider G, Munir AA, Sohoo NA. Frequency, intensity and impact of premenstrual syndrome in medical students. J Coll Physicians Surg Pak. 2008;18(8):481-484.
9. Lee AM, So-Kum Tang C, Chong C. A culturally sensitive study of premenstrual and menstrual symptoms among Chinese women. J Psychosom Obstet Gynaecol. 2009;30(2):105-114.
10. Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med. 1998;338(4):209-216.
11. Freeman EW, Sammel MD, Rinaudo PJ, Sheng L. Premenstrual syndrome as a predictor of menopausal symptoms. Obstet Gynecol. 2004;103(5 pt 1):960-966.
12. Rosenfeld R, Livne D, Nevo O, et al. Hormonal and volume dysregulation in women with premenstrual syndrome. Hypertension. 2008;51(4):1225-1230.
13. Condon JT. The premenstrual syndrome: a twin study. Br J Psychiatry. 1993;162:481-486.
14. Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP): reliability and validity. Arch Womens Ment Health. 2006;9(1):41-49.
15. Borenstein JE, Dean BB, Yonkers KA, Endicott J. Using the daily record of severity of problems as a screening instrument for premenstrual syndrome. Obstet Gynecol. 2007;109(5):1068-1075.
16. Daley A. Exercise and premenstrual symptomatology: a comprehensive review. J Womens Health (Larchmt). 2009;18(6):895-899.
17. Bertone-Johnson ER, Hankinson SE, Bendich A, Johnson SR, Willett WC, Manson JE. Calcium and vitamin D intake and risk of incident premenstrual syndrome. Arch Intern Med. 2005;165(11):1246-1252.
18. Bertone-Johnson ER, Chocano-Bedoya PO, Zagarins SE, Micka AE, Ronnenberg AG. Dietary vitamin D intake, 25-hydroxyvitamin D3 levels and premenstrual syndrome in a college-aged population. J Steroid Biochem Mol Biol. 2010;121(1-2):434-437.
19. Thys-Jacobs S, Starkey P, Bernstein D, Tian J. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am J Obstet Gynecol. 1998;179(2):444-452.
20. Lustyk MK, Gerrish WG, Shaver S, Keys SL. Cognitive-behavioral therapy for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Arch Womens Ment Health. 2009;12(2):85-96.
21. Whelan AM, Jurgens TM, Naylor H. Herbs, vitamins and minerals in the treatment of premenstrual syndrome: a systematic review. Can J Clin Pharmacol. 2009;16(3):e407-e429.
22. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ. 2001;322(7279):134-137.
23. Wyatt KM, Dimmock PW, Jones PW, Shaughn O'Brien PM. Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. BMJ. 1999;318(7195):1375-1381.
24. Brown J, O'Brien PM, Marjoribanks J, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2009;(2):CD001396.
25. Freeman EW, Rickels K, Yonkers KA, Kunz NR, McPherson M, Upton GV. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol. 2001;98(5 pt 1):737-744.
26. Steiner M, Pearlstein T, Cohen LS, et al. Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs. J Womens Health (Larchmt). 2006;15(1):57-69.
27. U.S. Food and Drug Administration. MedWatch safety alerts. Paroxetine HCI-Paxil and generic paroxetine. December 2005. http://www.fda.gov/Safety/MedWatch/ucm152062.htm. Accessed May 14, 2011.
28. Graham CA, Sherwin BB. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res. 1992;36(3):257-266.
29. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. 2009;(2):CD006586.
30. Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 2005;106(3):492-501.
31. Megivern D. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med. 2002;11(2):95-96.
32. Coffee AL, Kuehl TJ, Willis S, Sulak PJ. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Am J Obstet Gynecol. 2006;195(5):1311-1319.
33. Jarvis CI, Lynch AM, Morin AK. Management strategies for premenstrual syndrome/premenstrual dysphoric disorder. Ann Pharmacother. 2008;42(7):967-978.
34. Freeman EW, Rickels K, Sondheimer SJ, Polansky M. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA. 1995;274(1):51-57.
35. Landén M, Eriksson O, Sundblad C, Andersch B, Naessén T, Eriksson E. Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo. Psychopharmacology (Berl). 2001;155(3):292-298.
36. Wang M, Hammarbäck S, Lindhe BA, Bäckström T. Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. Acta Obstet Gynecol Scand. 1995;74(10):803-808.